- PackSize
- 50ug/100ug
- Target
- von Willebrand antigen II
- Reactivity
- Human
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Humanized
- Isotype
- VH-VH
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 20 mM citric acid, 6.2% sucrose, 0.01% Tween80
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% purity as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- von Willebrand antigen II, von Willebrand factor, F8VWF, vWF, VWF
- Species
- --
- Gene ID-1
- P04275
- Uniprot
- --
- Background
- Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP).<br>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --